Choosing Primary vs. Composite Endpoints in Orphan Drug Studies
In rare disease clinical trials, defining suitable endpoints is one of the most critical and complex tasks. With small populations, heterogeneous symptoms, and limited natural history data, selecting the right efficacy measure directly impacts trial success and regulatory approval.
Click to read the full article.
